HealthEquity (NASDAQ:HQY – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 3.570-3.740 for the period, compared to the consensus estimate of 3.760. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on HQY. Mizuho assumed coverage on HealthEquity in a research note on Wednesday, December 4th. They set an “outperform” rating and a $126.00 target price for the company. Raymond James raised their price target on shares of HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 25th. JMP Securities raised their price target on shares of HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 10th. Royal Bank of Canada raised their price target on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Wells Fargo & Company raised their price target on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $112.92.
Read Our Latest Analysis on HQY
HealthEquity Price Performance
HealthEquity (NASDAQ:HQY – Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.16). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. Equities analysts expect that HealthEquity will post 2.32 EPS for the current year.
Insider Activity at HealthEquity
In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction on Monday, February 10th. The shares were sold at an average price of $111.29, for a total value of $639,917.50. Following the sale, the director now directly owns 78,219 shares in the company, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.20% of the stock is owned by insiders.
About HealthEquity
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Read More
- Five stocks we like better than HealthEquity
- Differences Between Momentum Investing and Long Term Investing
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Must-Own Stocks to Build Wealth This Decade
- Business Services Stocks Investing
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.